Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
产品特性
This is a synthetic peptide designed for use in combination with anti-FLJ11730 antibody (Catalog #: ARP33354_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
限制
仅限研究用
状态
Lyophilized
溶解方式
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
浓度
1 mg/mL
缓冲液
Final peptide concentration is 1 mg/mL in PBS.
注意事项
Avoid repeated freeze-thaw cycles.
储存条件
-20 °C
储存方法
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
抗原
FLJ11730
背景
The screening of cDNA expression libraries from human tumors with serum antibody (SEREX) has proven to be a powerful method for identifying the repertoire of tumor antigens recognized by the immune system of cancer patients, referred to as the cancer immunome. In this regard, cancer/testis (CT) antigens are of particular interest because of their immunogenicity and restricted expression patterns. Synoivial sarcomas are striking with regard to CT antigen expression, however, highly expressed in sarcoma, CT antigens do not induce frequent humoral immune responses in sarcoma patients. Sera from two patients were used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting in the identification of 113 distinct antigens. Sarcoma antigen NY-SAR-91 is one of them.
Alias Symbols: Eaf6, CENP-28, C1orf149, CDABP0189, NY-SAR-91, RP3-423B22.2, FLJ11730
Protein Interaction Partner: C20orf20,CCDC85B,FXR2,L3MBTL2,CCDC85B,FXR2,ING3,ING4,ING5,L3MBTL2,MYST2,PHF17